Clinical and Genomic Characteristics of Adult Diffuse Midline Glioma
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Purpose The treatment outcomes and genomic profiles of diffuse midline glioma (DMG) in adult patients are rarely characterized. We performed a retrospective study to evaluate the clinicogenomic profiles of adult patients with brain DMG. Materials and Methods Patients aged ≥ 18 years diagnosed with brain DMG at Seoul National University Hospital were included. The clinicopathological parameters, treatment outcomes, survival, and genomic profiles using 82-gene targeted next-generation sequencing (NGS) were analyzed. The 6-month progression-free survival (PFS6) after radiotherapy and overall survival (OS) were evaluated. Results Thirty-three patients with H3-mutant brain DMG were identified. The median OS from diagnosis was 21.8 months (95% confidence interval [CI], 13.2 to not available [NA]) and involvement of the ponto-medullary area tended to have poor OS (median OS, 20.4 months [95% CI, 9.3 to NA] vs. 43.6 months [95% CI, 18.2 to NA]; p=0.07). Twenty-four patients (72.7%) received radiotherapy with or without temozolomide. The PFS6 rate was 83.3% (n=20). Patients without progression at 6 months showed significantly prolonged OS compared with those with progression at 6 months (median OS, 24.9 months [95% CI, 20.4 to NA] vs. 10.8 months [95% CI, 4.0 to NA]; p=0.02, respectively). Targeted NGS was performed in 13 patients with DMG, among whom nine (69.2%) harbored concurrent TP53 mutation. Two patients (DMG14 and DMG23) with PIK3CAR38S+E545K and KRASG12A mutations received matched therapies. Patient DMG14 received sirolimus with a PFS of 8.4 months. Conclusion PFS6 after radiotherapy was associated with prolonged survival in adult patients with DMG. Genome-based matched therapy may be an encouraging approach for progressive adult patients with DMG.
Abstract
Purpose The treatment outcomes and genomic profiles of diffuse midline glioma (DMG) in adult patients are rarely characterized. We performed a retrospective study to evaluate the clinicogenomic profiles of adult patients with brain DMG. Materials and Methods Patients aged ≥ 18 years diagnosed with brain DMG at Seoul National University Hospital were included. The clinicopathological parameters, treatment outcomes, survival, and genomic profiles using 82-gene targeted next-generation sequencing (NGS) were analyzed. The 6-month progression-free survival (PFS6) after radiotherapy and overall survival (OS) were evaluated. Results Thirty-three patients with H3-mutant brain DMG were identified. The median OS from diagnosis was 21.8 months (95% confidence interval [CI], 13.2 to not available [NA]) and involvement of the ponto-medullary area tended to have poor OS (median OS, 20.4 months [95% CI, 9.3 to NA] vs. 43.6 months [95% CI, 18.2 to NA]; p=0.07). Twenty-four patients (72.7%) received radiotherapy with or without temozolomide. The PFS6 rate was 83.3% (n=20). Patients without progression at 6 months showed significantly prolonged OS compared with those with progression at 6 months (median OS, 24.9 months [95% CI, 20.4 to NA] vs. 10.8 months [95% CI, 4.0 to NA]; p=0.02, respectively). Targeted NGS was performed in 13 patients with DMG, among whom nine (69.2%) harbored concurrent TP53 mutation. Two patients (DMG14 and DMG23) with PIK3CAR38S+E545K and KRASG12A mutations received matched therapies. Patient DMG14 received sirolimus with a PFS of 8.4 months. Conclusion PFS6 after radiotherapy was associated with prolonged survival in adult patients with DMG. Genome-based matched therapy may be an encouraging approach for progressive adult patients with DMG.
참고문헌 (36)
- Louis DN, "The 2016 World Health Organization classification of tumors of the central nervous system : a summary", Acta Neuropathol, 131, pp.803~820 (2016)
- Gielen GH, "H3F3A K27M mutation in pediatric CNS tumors : a marker for diffuse high-grade astrocytomas", Am J Clin Pathol, 139, pp.345~349 (2013)
- Karremann M, "Diffuse high-grade gliomas with H3 K27M mutations carry a dismal prognosis independent of tumor location", Neuro Oncol, 20, pp.123~131 (2018)
- Mackay A, "Integrated molecular meta-analysis of 1, 000pediatric high-grade and diffuse intrinsic pontine glioma", Cancer Cell, 32, pp.520~537 (2017)
- Schwartzentruber J, "Driver mutations in histone H3.3 and chromatin remodelling genes in paediatric glioblastoma", Nature, 482, pp.226~231 (2012)
- Buczkowicz P, "Genomic analysis of diffuse intrinsic pontine gliomas identifies three molecular subgroups and recurrent activating ACVR1 mutations", Nat Genet, 46, pp.451~456 (2014)
- Aihara K, "H3F3A K27M mutations in thalamic gliomas from young adult patients", Neuro Oncol, 16, pp.140~146 (2014)
- Meyronet D, "Characteristics of H3 K27Mmutant gliomas in adults", Neuro Oncol, 19, pp.1127~1134 (2017)
- Rodon J, "Genomic and transcriptomic profiling expands precision cancer medicine : the WINTHER trial", Nat Med, 25, pp.751~758 (2019)
- Stupp R, "Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma", N Engl J Med, 352, pp.987~996 (2005)
- Sulman EP, "Radiation therapy for glioblastoma : American Society of Clinical Oncology clinical practice guideline endorsement of the American Society for Radiation Oncology guideline", J Clin Oncol, 35, pp.361~369 (2017)
- Wen PY, "Updated response assessment criteria for high-grade gliomas : response assessment in neuro-oncology working group", J Clin Oncol, 28, pp.1963~1972 (2010)
- Ballman KV, "The relationship between six-month progression-free survival and 12-month overall survival end points for phase II trials in patients with glioblastoma multiforme", Neuro Oncol, 9, pp.29~38 (2007)
- Li H, "Exploring single-sample SNP and INDEL calling with whole-genome de novo assembly", Bioinformatics, 28, pp.1838~1844 (2012)
- Van der Auwera GA, "From FastQ data to high confidence variant calls : the Genome Analysis Toolkit best practices pipeline", Curr Protoc Bioinformatics, 43, pp.11~ (2013)
- Wilm A, "LoFreq : a sequence-quality aware, ultra-sensitive variant caller for uncovering cell-population heterogeneity from high-throughput sequencing datasets", Nucleic Acids Res, 40, pp.11189~11201 (2012)
- Rausch T, "DELLY : structural variant discovery by integrated paired-end and split-read analysis", Bioinformatics, 28, pp.i333~9 (2012)
- Chen X, "Manta : rapid detection of structural variants and indels for germline and cancer sequencing applications", Bioinformatics, 32, pp.1220~1222 (2016)
- Oesper L, "Quantifying tumor heterogeneity in whole-genome and whole-exome sequencing data", Bioinformatics, 30, pp.3532~3540 (2014)
- Talevich E, "CNVkit : genomewide copy number detection and visualization from targeted DNA sequencing", PLoS Comput Biol, 12, pp.e1004873~ (2016)
- Cingolani P, "A program for annotating and predicting the effects of single nucleotide polymorphisms, SnpEff : SNPs in the genome of Drosophila melanogaster strain w1118; iso-2; iso-3", Fly(Austin), 6, pp.80~92 (2012)
- O’Leary NA, "Reference sequence(RefSeq)database at NCBI : current status, taxonomic expansion, and functional annotation", Nucleic Acids Res, 44, pp.D733~45 (2016)
- Tate JG, "COSMIC : the Catalogue Of Somatic Mutations In Cancer", Nucleic Acids Res, 47, pp.D941~7 (2019)
- Sherry ST, "dbSNP : the NCBI database of genetic variation", Nucleic Acids Res, 29, pp.308~311 (2001)
- Landrum MJ, "ClinVar : public archive of relationships among sequence variation and human phenotype", Nucleic Acids Res, 42, pp.D980~5 (2014)
- Lek M, "Analysis of protein-coding genetic variation in 60, 706 humans", Nature, 536, pp.285~291 (2016)
- Nikbakht H, "Spatial and temporal homogeneity of driver mutations in diffuse intrinsic pontine glioma", Nat Commun, 7, pp.11185~ (2016)
- Schreck KC, "Incidence and clinicopathologic features of H3 K27M mutations in adults with radiographically-determined midline gliomas", J Neurooncol, 143, pp.87~93 (2019)
- Larson JD, "Histone H3.3 K27M accelerates spontaneous brainstem glioma and drives restricted changes in bivalent gene expression", Cancer Cell, 35, pp.140~155 (2019)
- Lewis PW, "Inhibition of PRC2 activity by a gainof-function H3 mutation found in pediatric glioblastoma", Science, 340, pp.857~861 (2013)
- Chan KM, "The histone H3.3K27M mutation in pediatric glioma reprograms H3K27 methylation and gene expression", Genes Dev, 27, pp.985~990 (2013)
- Sturm D, "Hotspot mutations in H3F3A and IDH1define distinct epigenetic and biological subgroups of glioblastoma", Cancer Cell, 22, pp.425~437 (2012)
- Jung KS, "Pilot study of sirolimus in patients with PIK3CA mutant", amplified refractory solid cancer, 2017, pp.7, 27~31
- Lin GL, "Therapeutic strategies for diffuse midline glioma from high-throughput combination drug screening", Sci Transl Med, 11, pp.eaaw0064~ (2019)
- Hirohito Yamaguchi, "Regulation and Role of EZH2 in Cancer", Cancer Research and Treatment, 46(3), pp.209~222 (2014), 대한암학회
- Mohammad F, "EZH2 is a potential therapeutic target for H3K27M-mutant pediatric gliomas", Nat Med, 23, pp.483~492 (2017)